Mydriatic and cycloplegic drugs: a review of ocular and systemic complications.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic search or meta-analytic methodology
What was done
This paper is a narrative review summarizing the ocular and systemic adverse complications associated with the clinical administration of mydriatic and cycloplegic drugs.
What was found
The abstract reports no numerical data, incidence rates, or statistical comparisons. It qualitatively reports that complications are rare relative to extensive clinical use and often dose-related. Listed ocular complications include increased intraocular pressure, corneal and conjunctival pigmentation, anterior chamber pigment, lacrimal duct blockage, macular edema, corneal endothelium damage, hyperemia, allergy, discomfort, and blurred vision. Listed systemic complications include tachycardia, hypertension, headache, faintness, pallor, trembling, excessive sweating, palpitations, arrhythmias, confusion, hallucinations, drowsiness, ataxia, flushed skin, high fever, dysarthria, thirst, dry mouth, convulsions, disorientation, nervousness, coma, and death.
Why it matters
The paper catalogs potential localized and systemic adverse reactions to ophthalmic sympathomimetic and parasympatholytic medications for clinicians.
Limits
The abstract provides no quantitative data, incidence estimates, or systematic search methodology. It does not stratify risk by specific chemical agent, formulation, dosage, or patient demographic factors.
Cited by
- supports High systemic doses of antimuscarinic medications commonly induce side effects such as dry mouth and tachycardia.